15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Tenaya Therapeutics Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $3.00 to $8.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $5.33 sits 609% above the current $0.75. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Tenaya Therapeutics Inc.
As of Jul, 3 of 3 firms rate TNYA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TNYA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.14 – $-0.08 · 7 analysts · -18% YoY
Next period, 7 analysts expect Tenaya Therapeutics Inc to earn $-0.10 a share (range $-0.14 – $-0.08), versus $-0.12 a year earlier. Full-year consensus is $-0.38, growing to $-0.41 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $8.5M, rising to $0 next year.
Top analysts covering Tenaya Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNYA.
#1
Geulah Livshits
Chardan Capital · Rank #100
Buy
$8.00+963.7% to target
Overall win rate
44%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$40.00+5218.4% to target
Overall win rate
34%
+ Follow
#3
Matthew Harrison
Morgan Stanley · Rank #243
Buy
$5.00+564.8% to target
Overall win rate
44%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$3.00+298.9% to target
Overall win rate
32%
+ Follow
#5
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$18.00+2293.3% to target
Overall win rate
22%
+ Follow
TNYA stock forecast FAQ
What is TNYA's average 12-month price target?+
The 3 analysts with a live target average $5.33 for Tenaya Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $3.00 low.
Is TNYA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TNYA?+
The Street-high target is $8.00 (Chardan Capital), and the Street-low is $3.00 (HC Wainwright & Co.). The average of all 3 active targets is $5.33.
How many Wall Street analysts cover TNYA?+
3 analysts have an active rating on Tenaya Therapeutics Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering TNYA?+
Among analysts who currently cover TNYA, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #100). Their current call is Buy with a $8.00 target.
What is Tenaya Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.14 – $-0.08) across 7 analysts. Full-year EPS is projected at $-0.38, rising to $-0.41 the following year.
How much revenue is Tenaya Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $8.5M, growing to $0 next year.
Have analysts been upgrading or downgrading TNYA lately?+
As of Jul, 3 of 3 firms rate TNYA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNYA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
